In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Pharmaceutical
La Jolla, California-based immunology specialist Equillium and Metacrine have entered into a definitive merger agreement whereby Equillium will acquire Metacrine in an all-stock transaction, edging the latter’s shares up 2.7% to $0.47 by close of trading on Tuesday. 7 September 2022
Biotechnology
STORM Therapeutics, a UK biotech discovering and developing small molecule therapies targeting RNA modification enzymes for oncology and other diseases, has announced the appointment of Gerald McMahon as president, chief executive and board director. 7 September 2022
Biotechnology
The latest in a series of Industry Leader pieces from biological reagent supplier and service provider Sino Biological. 6 September 2022
Biotechnology
The US Food and Drug Administration has lifted a clinical hold on research into SRP-5051, a candidate under development by rare disease company Sarepta Therapeutics. 6 September 2022
Biotechnology
US biopharma Iveric Bio has announced positive top-line results from GATHER2, the company’s second Phase III trial of Zimura (avacincaptad pegol), a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA). 6 September 2022
Biotechnology
New findings from the XALOC program support the real-world effectiveness of UK pharma major AstraZeneca’s Fasenra (benralizumab) in the management of patients with severe eosinophilic asthma (SEA), showing reductions in annualized asthma exacerbation rate (AAER), improvements in asthma control and the ability to achieve clinical remission. 6 September 2022
Pharmaceutical
Confirming an earlier reimbursement decision, leading PARP blocker Lynparza (olaparib) has not been recommended for regular use in England and Wales, dealing a blow to people with prostate cancer. 6 September 2022
Biotechnology
Nodus Oncology, a novel biotech company focused on developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets, has launched with seed funding from Cumulus Oncology and announced a partnership with the Lead Discovery Center (LDC). 6 September 2022
Generics
The retiring Roger Scarlett-Smith is to be replaced as head of UK at Germany’s STADA Arzneimittel (SAZ: Xetra) by Rudolf Bär. 6 September 2022
Biotechnology
Dutch antibody-drug conjugate (ADC) specialist Synaffix and Germany’s Emergence Therapeutics today announced they have entered into a licensing agreement, providing Emergence access on a target-specific basis to Synaffix’ proprietary antibody drug conjugate (ADC) technologies comprising GlycoConnect, HydraSpace and SYNtecan E linker-payload. 6 September 2022
Biotechnology
CanSino Biologics has announced that the National Medical Products Administration of China (NMPA) has granted the company emergency use authorization for its recombinant COVID-19 vaccine (Adenovirus Type 5 Vector) for Inhalation, trade name Convidecia Air, to be used as a booster dose. 6 September 2022
Biotechnology
UK-based biotech PhoreMost, which is dedicated to ‘Drugging the Undruggable’ disease targets, today announced it has entered into a multi-project target discovery collaboration with Swiss pharma giant Roche. 6 September 2022
Biotechnology
Avance Clinical, an Australian clinical research organization CRO) for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates, enabling biotech clients a seamless journey from early phase to later phase studies. 6 September 2022
Pharmaceutical
The Drugs for Neglected Diseases initiative (DNDi) has announced Dr Luis Pizarro as its new executive director, who will replace Bernard Pécoul, who has served in the role for almost 20 years. 5 September 2022
Biotechnology
Dammam Valley, based in the Kingdom of Saudi Arabia, in partnership with other investment partners, announced they are to acquire a majority stake in Germany’s Arcensus GmbH. 5 September 2022
Pharmaceutical
Phase III data from the InPedILD trial, which assessed the pharmacokinetics (dosing) and safety profile of Ofev (nintedanib) in children and adolescents between six and 17 years old with clinically significant fibrosing interstitial lung disease (ILD), German family-owned pharma major Boehringer Ingelheim announced today. 5 September 2022
Biotechnology
Chinese biotech Hutchmed is continuing its transition from a development stage company into a global commercial organization, according to analyst Trinity Delta. 5 September 2022
Pharmaceutical
Shares of Israel-headquartered PolyPid closed down more than 73% on Friday, and a further 9% to $1.43 in after-hours trading, as the company revealed disappointing results for its lead drug candidate. 5 September 2022
Pharmaceutical
Pharma exports from Sweden have increased sharply during the first half of this year, figures show. 5 September 2022
Pharmaceutical
The likelihood of approval for the amyotrophic lateral sclerosis (ALS) candidate AMX0035 appeared to fade on Friday, following the release of downbeat briefing papers from the US regulator. 5 September 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze